Topic:

M&A

Latest Headlines

Latest Headlines

UPDATED: Perrigo snaps up OTC specialist Omega in deal worth $4.5B

Perennial dealmaker Perrigo signed on the dotted line for Belgium's Omega Pharma, elbowing past rival bidders to expand its footprint in the global OTC market.  

Allergan loses fight to block Ackman from voting for a Valeant takeover

Valeant and partner Bill Ackman have dodged a serious roadblock in their quest to acquire Allergan. A 9.7% roadblock, if you will.

Allergan discloses a secret admirer looking to make an offer. Could it be... Actavis?

Amid a heated takeover fight with Valeant, Allergan says it's got a mystery suitor. But according to The Wall Street Journal 's sources, it's not all that mysterious.

AstraZeneca builds cancer R&D dream house with $150M Definiens buyout, J&J deal

Looking to build an oncology powerhouse, AstraZeneca has scooped up the diagnostics player Definiens with a down payment of $150 million while executing another drug development partnership with J&J and Pharmacyclics to add to its growing portfolio of immuno-oncology deals

Covidien sells drug-coated balloon for $30M to appease regulators as it barrels toward Medtronic merger

Another hurdle toward the long-anticipated closure of Covidien's $43 billion merger with Medtronic was crossed today. Covidien announced that it is selling its clinical-stage Stellarex drug-coated angioplasty balloon for peripheral artery disease to Spectranetics for $30 million.

LabCorp is buying Covance for $5.6B to cut in on the CRO boom

Diagnostics giant LabCorp is buying its way into the upper ranks of the CRO business, signing a deal to pay $5.6 billion for Covance and create an end-to-end testing conglomerate.

IDEXX follows positive earnings with acquisition of Animana

Shares of IDEXX Laboratories rose nearly 5% to $141.67 last week after reporting third-quarter net income that handily beat analyst estimates and announcing the acquisition of Netherlands-based Animana, which makes software for veterinary practices.

Timely deals boost Charles River's balance sheet

A string of acquisitions has revenue rolling at Charles River Laboratories, and the CRO has inked another M&A deal it hopes will pay off with a larger market share.

After strong Q3, no $55B deals in AbbVie's future, CEO says. But a smaller one? Maybe

No Shire? No problem for AbbVie. At least, for now.

Zimmer Biomet will be created amid executive shake-up

The long-anticipated acquisition of Biomet by Zimmer Holdings is almost slated to close. The resulting entity will be known as Zimmer Biomet; it has already unveiled a planned new organizational structure and an executive team that draws heavily on the soon-to-be-incorporated Biomet. The deal to create this musculoskeletal giant is expected to close during the first quarter of 2015.